Freedom of Information request on non-clinical study TOX9587(FOI 21-366)
Published 28 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-3-may-2021/freedom-of-information-request-on-non-clinical-study-tox9587foi-21-366
6th May 2021 FOI 21/366 Dear
Thank you for your email.
Regarding your request for the non-clinical study TOX9587 (a 1-month Repeated-Dose Oral Toxicity Study of JNJ-212082-AAA in rats with integrated Irwin observations (impurity qualification)) and the specification for Zytiga 500 mg film-coated tablets (abiraterone acetate), this was approved by a centralised procedure through the European Commission (EC) and the European Medicines Agency (EMA - EU/1/11/714/002-003).
We consider that disclosure of this information is likely to damage the MHRA’s relationship with another regulator or country, and thus could damage the UK’s interests abroad. Section 27 is a qualified exemption, which means that we have considered whether the public interest in releasing the information is outweighed by the public interest in not giving the information. In favour of disclosure, we consider that there is a general public benefit from releasing documentation related to Zytiga 500mg. However, we consider that the public interest will be better served by not releasing the information as this product is granted by an EC decision, the data submitted would need to be considered by the EMA for release.
We advise that you contact the EMA directly for this information.
If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.
If you have a query about the information provided, please reply to this email
If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: [email protected]
Due to the ongoing Covid-19 situation, we are not able to accept delivery of any documents or correspondence by post or courier to any of our offices
Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF
Yours sincerely
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency 10 South Colonnade, Canary Wharf, London E14 4PU